Buske, C <br/><br/>
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).  [electronic resource] 

 -  Leukemia  Jan 2009 
 - 153-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2008.261  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--therapeutic use<br/>Disease-Free Survival<br/>Doxorubicin--therapeutic use<br/>Humans<br/>Middle Aged<br/>Prednisone--therapeutic use<br/>Remission Induction<br/>Rituximab<br/>Treatment Outcome<br/>Vincristine--therapeutic use<br/>Waldenstrom Macroglobulinemia--drug therapy